Stephan Moll, MD writes….
The pharmaceutical company Portola reported today (May 8th, 2013) on the findings of their human volunteer study of their blood thinner antidote PRT4445 (ClinicalTrials.gov Identifier: NCT01758432 – medical details of the study design are here, study NCT01758432. This dug is in early development. In the study, healthy volunteers who had taken the new oral blood thinner Eliquis (Apixaban) received the reversal agent. The study showed a “rapid and sustained and dose-related reversal” of the blood thinning effect of Eliquis” and “no serious adverse events”.
The full Portola report is here. The data of the study still need to be presented at a medical meeting, peer-reviewed and published. It is far too early to tell whether the drug has any clinical efficacy in major bleeding associated with Eliquis or any of the other new oral anti-Xa blood thinners, such as Xarelto (rivaroxaban) or Edoxaban ( a drug not approved or available in the U.S.).
Disclosure: I have consulted for Janssen, Boehringer-Ingelheim, and Daiichi.
Last updated: May 8th, 2013